Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX 株式レポート

時価総額:US$274.5m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Black Diamond Therapeutics 将来の成長

Future 基準チェック /06

Black Diamond Therapeuticsの収益は年間7.7%で減少すると予測されていますが、年間収益は年間81.9%で増加すると予想されています。EPS は年間4.8%で増加すると予想されています。

主要情報

-7.7%

収益成長率

4.8%

EPS成長率

Biotechs 収益成長24.7%
収益成長率81.9%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日07 Jun 2024

今後の成長に関する最新情報

Recent updates

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16
We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11
We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05
What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01
Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond nominates development candidate for glioblastoma program

Nov 20

Black Diamond Therapeutics EPS beats by $0.02

Nov 10

Black Diamond Therapeutics: One To Watch In Precision Oncology Space

Oct 23

業績と収益の成長予測

NasdaqGS:BDTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20264-135-125-1175
12/31/2025N/A-110-94-1006
12/31/2024N/A-82-73-706
3/31/2024N/A-80-68-68N/A
12/31/2023N/A-82-67-67N/A
9/30/2023N/A-84-75-75N/A
6/30/2023N/A-83-73-73N/A
3/31/2023N/A-87-77-77N/A
12/31/2022N/A-91-85-85N/A
9/30/2022N/A-96-88-87N/A
6/30/2022N/A-109-99-97N/A
3/31/2022N/A-121-107-104N/A
12/31/2021N/A-126-103-100N/A
9/30/2021N/A-122-94-92N/A
6/30/2021N/A-105-78-77N/A
3/31/2021N/A-85-65-65N/A
12/31/2020N/A-67-52-52N/A
9/30/2020N/A-55-44-44N/A
6/30/2020N/A-46-38-38N/A
3/31/2020N/A-44-29-29N/A
12/31/2019N/A-35-25-25N/A
9/30/2019N/A-28-20-20N/A
6/30/2019N/A-22-16-16N/A
3/31/2019N/A-11-13-13N/A
12/31/2018N/A-9-9-8N/A

アナリストによる今後の成長予測

収入対貯蓄率: BDTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BDTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BDTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BDTX来年は収益がないと予測されています。

高い収益成長: BDTX来年は収益がないと予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: BDTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘